Neurocrine announces new data from Phase 4 KINECT-PRO study

Neurocrine (NBIX) Biosciences announced new data from the Phase 4 KINECT-PRO open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale. Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24. Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment. The Tardive Dyskinesia Impact Scale is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. These results were presented at 2025 Psych Congress Elevate in Las Vegas.